NCT07085507RecruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Escalation Study in Healthy Participants and an Expansion Cohort in Adult Patients With Multiple Sclerosis to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
Part 1 of this study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VT7208 in healthy volunteers. Part 2 of this study will be an open-label, randomized study to characterize the effect of food on the pharmacokinetics of VT7208 in healthy volunteers. Part 3 of this study will evaluate the safety of VT7208 as monotherapy in patients with MS.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 7 Jul 2025
- Start date
- Aug 2025
- Primary completion date
- Oct 2026
- Lead sponsor
- Vidya Therapeutics Inc
- Diseases
- Multiple sclerosis
- NCT number
- NCT07085507
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 100
- From Aug 2025 to the primary completion date, Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known history of illicit drug use or drug abuse, harmful alcohol use (at the -Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 7 days prior to the first dose of study agent
- Donation or loss of ≥ 1 unit of whole blood or plasma within 4 weeks prior to dosing
Other illness
- Evidence of clinically significant condition or disease
- Any physical or psychological condition that prohibits study completion
- History of severe allergic reactions or hypersensitivity
Who the study is looking for
- Parts 1 and 2
- Age 18-65
- Must be in good health with no significant medical history
- Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
- Able and willing to provide written informed consent
- Part 3
- Age 18-60
- Must be in good health with no significant medical history
- MS diagnosis prior to Day 1 in accordance with 2017 McDonald criteria.
- Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
- Able and willing to provide written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CMAX Coordinator of this site? Confirm its status | Adelaide | Australia | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.